
## Gianfranco Ferraccioli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5690495/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
2	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
3	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases, 2006, 66, 34-45.	0.9	651
4	Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood, 2003, 101, 3827-3834.	1.4	471
5	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 909-920.	0.9	394
6	2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases, 2017, 76, 948-959.	0.9	393
7	Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Research and Therapy, 2008, 10, R30.	3.5	387
8	Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An openâ€label extension analysis. Arthritis and Rheumatism, 2007, 56, 3896-3908.	6.7	310
9	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nature Medicine, 2020, 26, 1295-1306.	30.7	304
10	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.7	246
11	Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis and Rheumatism, 2002, 46, 2029-2033.	6.7	240
12	EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 31-35.	0.9	224
13	Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. Arthritis Research and Therapy, 2010, 12, R42.	3.5	217
14	Prednisone plus Methotrexate for Polymyalgia Rheumatica. Annals of Internal Medicine, 2004, 141, 493.	3.9	204
15	Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2006, 66, 143-150.	0.9	194
16	Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood, 1995, 86, 1887-1892.	1.4	174
17	Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 172-175.	0.9	172
18	Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology, 2006, 45, 842-846.	1.9	170

#	Article	IF	CITATIONS
19	Obesity and reduction of the response rate to anti–tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care and Research, 2013, 65, 94-100.	3.4	170
20	MicroRNA-155—at the Critical Interface of Innate and Adaptive Immunity in Arthritis. Frontiers in Immunology, 2017, 8, 1932.	4.8	170
21	The role of biosimilars in the treatment of rheumatic diseases. Annals of the Rheumatic Diseases, 2013, 72, 322-328.	0.9	166
22	B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Research and Therapy, 2010, 12, R54.	3.5	162
23	Remission and rheumatoid arthritis: Data on patients receiving usual care in twentyâ€four countries. Arthritis and Rheumatism, 2008, 58, 2642-2651.	6.7	156
24	A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 925-932.	4.5	146
25	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity Reviews, 2012, 12, 225-229.	5.8	146
26	Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: Clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis and Rheumatism, 2000, 43, 94-102.	6.7	142
27	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134
28	Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Seminars in Arthritis and Rheumatism, 2015, 44, 428-436.	3.4	130
29	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology, 2015, 54, 891-898.	1.9	129
30	Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. British Journal of Rheumatology, 2002, 41, 1346-1356.	2.3	124
31	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	5.6	122
32	Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: Potential utility of immunosuppressive therapy in cardiac damage progression. Seminars in Arthritis and Rheumatism, 2014, 43, 526-535.	3.4	119
33	TNF-?, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmunity Reviews, 2005, 4, 153-161.	5.8	118
34	Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Annals of the Rheumatic Diseases, 2013, 72, 858-862.	0.9	112
35	Obesity as a Risk and Severity Factor in Rheumatic Diseases (Autoimmune Chronic Inflammatory) Tj ETQq1 1 0.7	84314 rgB 4.8	T /Overlock 110
36	Salivary gland B cell lymphoproliferative disorders in Sjögren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. European Journal of Immunology, 2002, 32, 903.	2.9	104

#	Article	IF	CITATIONS
37	Twoâ€year clinical and radiographic results with combination etanercept–methotrexate therapy versus monotherapy in early rheumatoid arthritis: A twoâ€year, doubleâ€blind, randomized study. Arthritis and Rheumatism, 2010, 62, 674-682.	6.7	104
38	Body weight, gender and response to TNF-Â blockers in axial spondyloarthritis. Rheumatology, 2014, 53, 875-881.	1.9	104
39	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 20-33.	0.9	104
40	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
41	Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome. Arthritis and Rheumatism, 1997, 40, 318-331.	6.7	100
42	Interleukin-1β and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis. Molecular Medicine, 2010, 16, 552-557.	4.4	100
43	B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology, 2007, 46, 37-43.	1.9	99
44	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nature Communications, 2016, 7, 12970.	12.8	97
45	Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. Journal of Rheumatology, 2008, 35, 1256-64.	2.0	95
46	The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmunity Reviews, 2011, 10, 582-589.	5.8	90
47	Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, openâ€label, twelveâ€week study. Arthritis and Rheumatism, 2008, 59, 32-41.	6.7	89
48	Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clinical Rheumatology, 2011, 30, 1265-1275.	2.2	89
49	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. Rheumatology, 2012, 51, 157-168.	1.9	89
50	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	3.5	89
51	The need for personalised medicine for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 4-7.	0.9	88
52	Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Annals of the Rheumatic Diseases, 2002, 61, 358-361.	0.9	86
53	Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology, 2000, 31, 182-189.	7.3	83
54	Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clinical Rheumatology, 2016, 35, 1683-1689.	2.2	83

GIANFRANCO FERRACCIOLI

#	Article	IF	CITATIONS
55	Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. Journal of Rheumatology, 2008, 35, 1944-9.	2.0	82
56	Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin a. Arthritis and Rheumatism, 1996, 39, 1006-1015.	6.7	80
57	TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. Clinical Rheumatology, 2008, 27, 833-839.	2.2	80
58	Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Annals of the Rheumatic Diseases, 2013, 72, 583-589.	0.9	80
59	IL-1BandIL-1RNgene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics, 2006, 7, 683-695.	1.3	75
60	Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. Journal of the American Academy of Dermatology, 2009, 60, 426-435.	1.2	73
61	MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications, 2017, 8, 15877.	12.8	72
62	Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Annals of the Rheumatic Diseases, 2011, 70, 1292-1295.	0.9	71
63	Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?. Annals of the Rheumatic Diseases, 2017, 76, 1228-1236.	0.9	70
64	B cells in systemic sclerosis: A possible target for therapy. Autoimmunity Reviews, 2011, 10, 624-630.	5.8	68
65	Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology, 2014, 53, 2209-2213.	1.9	67
66	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology, 2015, 54, 792-797.	1.9	67
67	Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. Clinical Rheumatology, 2017, 36, 2151-2158.	2.2	67
68	The human salivary proteome: a critical overview of the results obtained by different proteomic platforms. Expert Review of Proteomics, 2012, 9, 33-46.	3.0	65
69	Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respiratory Research, 2005, 6, 96.	3.6	64
70	Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission. Arthritis Research and Therapy, 2016, 18, 39.	3.5	62
71	Peripheral neuropathy in essential mixed cryoglobulinaemia Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 116-120.	1.9	60
72	Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications. European Respiratory Journal, 2010, 35, 418-425.	6.7	60

GIANFRANCO FERRACCIOLI

#	Article	IF	CITATIONS
73	Mild Sialoadenitis: A Common Finding in Patients with Hepatitis C Virus Infection. Scandinavian Journal of Gastroenterology, 1994, 29, 940-942.	1.5	58
74	Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis and Rheumatism, 2002, 46, 2252-2254.	6.7	56
75	Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clinical Immunology, 2011, 138, 107-116.	3.2	55
76	Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. Arthritis Research and Therapy, 2013, 15, R66.	3.5	55
77	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clinical and Experimental Rheumatology, 2015, 33, 449-56.	0.8	55
78	Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 1847-50.	2.0	53
79	Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 2006, 80, 275-281.	4.7	52
80	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. Arthritis Research and Therapy, 2016, 18, 78.	3.5	52
81	Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome. PLoS ONE, 2016, 11, e0153012.	2.5	48
82	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Annals of the Rheumatic Diseases, 2006, 66, 249-252.	0.9	46
83	Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care and Research, 2011, 63, 711-720.	3.4	46
84	Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clinical Respiratory Journal, 2012, 6, 9-17.	1.6	46
85	Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Research and Therapy, 2018, 20, 75.	3.5	45
86	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. Clinical and Experimental Rheumatology, 2010, 28, S18-27.	0.8	45
87	Extrasalivary lymphoma development in Sjögren's syndrome: Clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis and Rheumatism, 2003, 48, 3181-3186.	6.7	43
88	PTPN22 1858C>T Polymorphism Distribution in Europe and Association with Rheumatoid Arthritis: Case-Control Study and Meta-Analysis. PLoS ONE, 2011, 6, e24292.	2.5	43
89	Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis. Medicine (United States), 2017, 96, e6656.	1.0	43
90	Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. European Journal of Internal Medicine, 2019, 60, 46-53.	2.2	43

#	Article	IF	CITATIONS
91	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 2020, 79, 453-459.	0.9	43
92	Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 29-33.	2.0	43
93	The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clinical and Experimental Rheumatology, 2014, 32, 869-77.	0.8	42
94	Widespread clonal B-cell disorder in Sjogren's syndrome predisposing to Helicobacter pylori-related gastric lymphoma. Gastroenterology, 1996, 110, 1969-1974.	1.3	41
95	An autosomal recessive <i>DNASE1L3</i> -related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus. Lupus, 2017, 26, 768-772.	1.6	40
96	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open, 2016, 2, e000221.	3.8	38
97	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. Journal of Leukocyte Biology, 2019, 106, 1063-1068.	3.3	38
98	True primary Sjögren's syndrome in a subset of patients with hepatitis C infection: a model linking chronic infection to chronic sialadenitis. Israel Medical Association Journal, 2002, 4, 1101-5.	0.1	38
99	Computer-Aided Quantification of Interstitial Lung Disease from High Resolution Computed Tomography Images in Systemic Sclerosis: Correlation with Visual Reader-Based Score and Physiologic Tests. BioMed Research International, 2015, 2015, 1-8.	1.9	37
100	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. Clinical Rheumatology, 2018, 37, 315-321.	2.2	37
101	Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis. EBioMedicine, 2015, 2, 2037-2045.	6.1	36
102	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 2015, 74, 963-969.	0.9	36
103	Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study. Reumatismo, 2017, 69, 30.	0.9	36
104	Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. International Journal of Clinical and Laboratory Research, 2000, 30, 67-73.	1.0	35
105	Preliminary Classification of Nonmalignant B Cell Proliferation in Sjögren's Syndrome: Perspectives on Pathobiology and Treatment Based on an Integrated Clinico-Pathologic and Molecular Study Approach. Blood Cells, Molecules, and Diseases, 2001, 27, 757-766.	1.4	35
106	Colour Doppler ultrasonography evaluation of vascularization in the wrist and finger joints in rheumatoid arthritis patients and healthy subjects. European Journal of Radiology, 2012, 81, 1834-1838.	2.6	35
107	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	3.5	35
108	Toll-Like Receptor 4 Mediates Endothelial Cell Activation Through NF-κB but Is Not Associated with Endothelial Dysfunction in Patients with Rheumatoid Arthritis. PLoS ONE, 2014, 9, e99053.	2.5	35

#	Article	IF	CITATIONS
109	The â^'670G>A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 584-590.	0.9	34
110	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. PLoS ONE, 2012, 7, e40362.	2.5	34
111	â^'238 and +489 TNF-α along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunology Letters, 2005, 96, 103-108.	2.5	33
112	Osteoporosis and bone metabolism in postmenopausal women with osteoarthritis of the hand. Menopause, 2006, 13, 462-466.	2.0	33
113	Modeling the Ternary Complex TCR-Vβ/CollagenII(261–273)/HLA-DR4 Associated with Rheumatoid Arthritis. PLoS ONE, 2010, 5, e11550.	2.5	32
114	The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discovery Medicine, 2011, 11, 413-24.	0.5	32
115	Thrombogenicity of TNFα in rheumatoid arthritis defined through biological probes: TNFα blockers. Autoimmunity Reviews, 2004, 3, 261-266.	5.8	30
116	Helicobacter pylori Associated Antigastric Autoantibodies: Role in Sjogren's Syndrome Gastritis. Helicobacter, 2004, 9, 46-53.	3.5	30
117	Prevalence and Determinants of Peripheral Microvascular Endothelial Dysfunction in Rheumatoid Arthritis Patients: A Multicenter Cross-Sectional Study. Mediators of Inflammation, 2018, 2018, 1-8.	3.0	30
118	ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Research and Therapy, 2009, 11, R163.	3.5	29
119	Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis. Drugs and Aging, 2009, 26, 395-402.	2.7	29
120	Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clinical and Experimental Immunology, 2018, 193, 13-23.	2.6	29
121	The polymerase chain reaction detects B cell clonalities in patients with SjA¶gren's syndrome and suspected malignant lymphoma. Journal of Rheumatology, 1994, 21, 1497-501.	2.0	29
122	Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus, 2006, 15, 76-79.	1.6	28
123	Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. Clinical Rheumatology, 2010, 29, 99-101.	2.2	28
124	Infections, B cell receptor activation and autoimmunity: Different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmunity Reviews, 2007, 7, 109-113.	5.8	27
125	Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors. Lupus, 2008, 17, 533-540.	1.6	27
126	B-Cell Subsets in the Joint Compartments of Seropositive and Seronegative Rheumatoid Arthritis (RA) and No-RA Arthritides Express Memory Markers and ZAP70 and Characterize the Aggregate Pattern Irrespectively of the Autoantibody Status. Molecular Medicine, 2011, 17, 901-909.	4.4	27

#	Article	IF	CITATIONS
127	Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 294.	3.5	27
128	Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 2655-2665.	2.2	27
129	GISEA: an Italian biological agents registry in rheumatology. Reumatismo, 2011, 63, 155-64.	0.9	26
130	Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. Rheumatology, 2013, 52, 622-622.	1.9	26
131	Local cytokine expression in the progression toward B cell malignancy in Sj¶gren's syndrome. Journal of Rheumatology, 1995, 22, 1674-80.	2.0	26
132	Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. Annals of the Rheumatic Diseases, 2007, 66, 1210-1215.	0.9	25
133	β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up. Respiratory Research, 2011, 12, 22.	3.6	25
134	Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clinical and Experimental Rheumatology, 2012, 30, S48-52.	0.8	25
135	Controlled multicenter trial of tiopronin and D-penicillamine for rheumatoid arthritis. Arthritis and Rheumatism, 1982, 25, 923-929.	6.7	24
136	Synovial Predictors of Differentiation to Definite Arthritis in Patients With Seronegative Undifferentiated Peripheral Inflammatory Arthritis: microRNA Signature, Histological, and Ultrasound Features. Frontiers in Medicine, 2018, 5, 186.	2.6	24
137	Proteomic approaches to Sjögren's syndrome: A clue to interpret the pathophysiology and organ involvement of the disease. Autoimmunity Reviews, 2010, 9, 622-626.	5.8	23
138	Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 1309-1315.	0.9	23
139	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARγ. Molecular and Cellular Endocrinology, 2013, 381, 80-87.	3.2	23
140	Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2015, 54, 1630-1639.	1.9	23
141	Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis. Frontiers in Medicine, 2018, 5, 207.	2.6	23
142	Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 116.	3.5	23
143	Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine, 2019, 63, 369-375.	2.3	23
144	Haematopoietic stem cell transplantation (HSCT) in a patient with Sjogren's syndrome and lung malt lymphoma cured lymphoma not the autoimmune disease. Annals of the Rheumatic Diseases, 2001, 60, 173b-173.	0.9	22

#	Article	IF	CITATIONS
145	MR imaging of atlantoaxial joint in early rheumatoid arthritis. Radiologia Medica, 2010, 115, 1111-1120.	7.7	22
146	Inclusion of Synovial Tissue–Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatmentâ€Naive Rheumatoid Arthritis Patients. Arthritis and Rheumatology, 2021, 73, 1601-1613.	5.6	22
147	Position paper of Italian rheumatologists on the use of biosimilar drugs. Clinical and Experimental Rheumatology, 2015, 33, 1-4.	0.8	22
148	Lack of Hcv Infection in Malignant, Cells Refutes the Hypothesis of a Direct Transforming Action of the Virus in the Pathogenesis of Hcv-Associated B-Cell Nhls. Tumori, 2002, 88, 400-406.	1.1	21
149	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine, 2014, 81, 508-512.	1.6	21
150	Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst. Scandinavian Journal of Rheumatology, 2017, 46, 78-80.	1.1	21
151	Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. Journal of Rheumatology, 1994, 21, 1332-4.	2.0	21
152	Hepatocyte growth factor and transforming growth factor β1 ratio at baseline can predict early response to cyclophosphamide in systemic lupus erythematosus nephritis. Arthritis and Rheumatism, 2006, 54, 3633-3639.	6.7	20
153	Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis. BMC Immunology, 2014, 15, 28.	2.2	20
154	Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons. Autoimmunity Reviews, 2017, 16, 1096-1102.	5.8	20
155	Immune-Guided Therapy of COVID-19. Cancer Immunology Research, 2022, 10, 384-402.	3.4	20
156	Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation. Discovery Medicine, 2012, 14, 379-88.	0.5	20
157	Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. Reumatismo, 2011, 60, 85-94.	0.9	19
158	Drug survival of adalimumab in patients with rheumatoid arthritis over 10Âyears in the real-world settings: high rate remission together with normal function ability. Clinical Rheumatology, 2016, 35, 2649-2656.	2.2	19
159	B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clinical and Experimental Immunology, 2017, 190, 291-292.	2.6	19
160	Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk. Rheumatology, 2015, 54, 1991-1999.	1.9	18
161	Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations. Expert Review of Clinical Immunology, 2016, 12, 751-762.	3.0	18
162	QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. International Journal of Cardiology, 2017, 239, 33.	1.7	18

#	Article	IF	CITATIONS
163	Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu. Journal of Clinical Pathology, 2018, 71, 620-625.	2.0	18
164	Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Medical Weekly, 2011, 141, w13211.	1.6	18
165	The Relevance of VDJ PCR Protocols in Detecting B-Cell Clonal Expansion in Lymphomas and Other Lymphoproliferative Disorders. Tumori, 1995, 81, 405-409.	1.1	17
166	The role of high-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on vascular endothelial growth factor. Clinical and Experimental Immunology, 2016, 184, 62-72.	2.6	17
167	The Role of High-Mobility Group Box-1 and Its Crosstalk with Microbiome in Rheumatoid Arthritis. Mediators of Inflammation, 2017, 2017, 1-11.	3.0	17
168	Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis. Scientific Reports, 2019, 9, 10420.	3.3	17
169	The pathogenesis of microthrombi in COVIDâ€19 cannot be controlled by DOAC: NETosis should be the target. Journal of Internal Medicine, 2021, 289, 420-421.	6.0	17
170	Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. Journal of Rheumatology, 1996, 23, 1539-42.	2.0	17
171	Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 1840-1844.	6.7	16
172	Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Human Immunology, 2009, 70, 360-373.	2.4	16
173	Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. Clinical Chemistry and Laboratory Medicine, 2010, 48, 829-34.	2.3	16
174	Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology, 2012, 51, v12-v21.	1.9	16
175	To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmunity Reviews, 2012, 11, 558-562.	5.8	16
176	Environmental Pollution by Benzene and PM10 and Clinical Manifestations of Systemic Sclerosis: A Correlation Study. International Journal of Environmental Research and Public Health, 2017, 14, 1297.	2.6	16
177	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	2.0	16
178	Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations. Clinical Immunology, 2020, 214, 108395.	3.2	16
179	Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA). Internal and Emergency Medicine, 2011, 6, 11-15.	2.0	15
180	Proteome analysis of biological fluids from autoimmuneâ€rheumatological disorders. Proteomics - Clinical Applications, 2011, 5, 78-89.	1.6	15

#	Article	IF	CITATIONS
181	Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography. Clinical Rheumatology, 2015, 34, 1181-1186.	2.2	15
182	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA). Reumatismo, 2016, 68, 126-136.	0.9	15
183	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. RMD Open, 2018, 4, e000667.	3.8	15
184	Haemophilus parasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis. Frontiers in Medicine, 2021, 8, 671018.	2.6	15
185	Mycophenolate mofetil and intravenous dexamethasone in the treatment of persistent lupus myelitis. Journal of Rheumatology, 2007, 34, 588-91.	2.0	15
186	Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. Clinical Immunology, 2009, 131, 98-108.	3.2	14
187	Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study. Journal of Rheumatology, 2017, 44, 241-247.	2.0	14
188	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. Joint Bone Spine, 2018, 85, 455-459.	1.6	14
189	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine, 2021, 88, 105062.	1.6	14
190	The B side of rheumatoid arthritis pathogenesis. Pharmacological Research, 2019, 149, 104465.	7.1	13
191	A vascular endothelial growth factor deficiency characterises scleroderma lung disease. Annals of the Rheumatic Diseases, 2012, 71, 1461-1465.	0.9	12
192	The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine (United States), 2016, 95, e5506.	1.0	12
193	Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. Scandinavian Journal of Rheumatology, 2018, 47, 351-359.	1.1	11
194	Basic immunology may lead to translational therapeutic rationale: SARS oVâ€2 and rheumatic diseases. European Journal of Clinical Investigation, 2020, 50, e13342.	3.4	11
195	Comprehensive review on intravertebral intraspinal, intrajoint, and intradiscal vacuum phenomenon: From anatomy and physiology to pathology. Modern Rheumatology, 2021, 31, 303-311.	1.8	11
196	Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2002, 61, 855-856.	0.9	10
197	Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles of the responders. Immunotherapy, 2018, 10, 807-821.	2.0	10
198	Selective Inhibitors of T Cell Receptor Recognition of Antigen–MHC Complexes for Rheumatoid Arthritis. ACS Medicinal Chemistry Letters, 2019, 10, 644-649.	2.8	10

#	Article	IF	CITATIONS
199	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clinical and Experimental Rheumatology, 2019, 37, 649-655.	0.8	10
200	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2018, 47, 619-629.	3.4	9
201	Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study. European Journal of Internal Medicine, 2019, 66, 57-61.	2.2	9
202	Which B-cell subset should we target in lupus?. Annals of the Rheumatic Diseases, 2013, 72, 1891-1892.	0.9	8
203	Biomarkers of Joint Damage in Rheumatoid Arthritis: Where Are We in 2013?. Journal of Rheumatology, 2013, 40, 1244-1246.	2.0	8
204	Drug survival on TNF inhibitors: 2003–2004 data from Italian National Register (GISEA Register). Annals of the Rheumatic Diseases, 2014, 73, e31-e31.	0.9	8
205	Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone. Journal of the American Geriatrics Society, 2016, 64, 672-374.	2.6	8
206	Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a <i>post hoc</i> analysis of a phase III trial. RMD Open, 2019, 5, e000934.	3.8	8
207	Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study. Frontiers in Medicine, 2021, 8, 613889.	2.6	8
208	Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. Journal of Rheumatology, 1995, 22, 1060-4.	2.0	8
209	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 1018-1028.	0.8	8
210	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. Journal of Clinical Rheumatology, 2015, 21, 349-354.	0.9	7
211	Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. Autoimmunity Reviews, 2019, 18, 317-324.	5.8	7
212	Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. Frontiers in Medicine, 2020, 7, 553075.	2.6	7
213	Pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatology, The, 2020, 2, e458.	3.9	7
214	Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology. Pharmacogenomics, 2004, 5, 1107-1116.	1.3	6
215	Pharmacogenetic of antirheumatic treatments: clinical implications. Pharmacogenomics Journal, 2007, 7, 2-9.	2.0	6
216	Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. RMD Open, 2016, 2, e000263.	3.8	6

#	Article	IF	CITATIONS
217	Correspondence on †Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'. Annals of the Rheumatic Diseases, 2023, 82, e5-e5.	0.9	6
218	Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. Annals of the Rheumatic Diseases, 2021, 80, e29-e29.	0.9	6
219	The chronic arthritis systemic index: a nomogram to assess the activity and severity of chronic arthritis. Arthritis and Rheumatism, 1993, 36, 1180-1181.	6.7	5
220	CYCLOSPORINE A PHARMACOKINETICS IN RHEUMATOID ARTHRITIS PATIENTS AFTER 6 MONTHS OF METHOTREXATE THERAPY. Pharmacological Research, 1999, 40, 483-486.	7.1	5
221	Atlantoepistrophic magnetic resonance imaging involvement in early rheumatoid arthritis: An aggressive tight control therapy not fully arresting the disease. Arthritis Care and Research, 2011, 63, 1629-1633.	3.4	5
222	ZAP-70+ B Cell Subset Influences Response to B Cell Depletion Therapy and Early Repopulation in Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 2276-2285.	2.0	5
223	Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients. Reumatismo, 2012, 64, 368-73.	0.9	5
224	Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression. Arthritis Research and Therapy, 2016, 18, 229.	3.5	5
225	Should rheumatoid factor (RF) (and antinuclear antibodies (ANA)) become routinary screening test for morbidities in the general population?. Autoimmunity Reviews, 2018, 17, 636-638.	5.8	5
226	Ultrasound assessment as predictor of disease relapse in children and adults with arthritis in clinical stable remission: new findings but still unmet needs. Annals of the Rheumatic Diseases, 2018, 77, 1391-1393.	0.9	5
227	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clinical and Experimental Rheumatology, 2017, 35, 660-665.	0.8	5
228	Peripheral blood CD4posCD25posFoxP3pos cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig. Arthritis Research and Therapy, 2022, 24, .	3.5	5
229	Tofacitinib for rheumatoid arthritis. Lancet, The, 2013, 381, 1812.	13.7	4
230	Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons?. Arthritis Research and Therapy, 2016, 18, 126.	3.5	4
231	CTLA-4 lg as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 315-7.	0.8	4
232	OP0178â€The Body Mass Index: A Determinant of Remission in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A113.2-A113.	0.9	3
233	Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al. Arthritis and Rheumatology, 2016, 68, 2052-2053.	5.6	3
234	Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus. BioMed Research International, 2018, 2018, 1-10.	1.9	3

#	Article	IF	CITATIONS
235	Measuring the Tâ€cell downâ€regulation of TCRâ€zeta, ZAPâ€70 and CD28 in arthritis patients: An old tool for new biomarkers. European Journal of Immunology, 2019, 49, 2195-2203.	2.9	3
236	More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia. Annals of the Rheumatic Diseases, 2022, 81, e157-e157.	0.9	3
237	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. Archives of Rheumatology, 2020, 35, 163-169.	0.9	3
238	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. Journal of Rheumatology, 2020, 47, 796-808.	2.0	3
239	Morbidity and Mortality From COVIDâ€19 Are Not Increased Among Children or Patients With Autoimmune Rheumatic Disease—Possible Immunologic Rationale: Comment on the Article by Henderson et al. Arthritis and Rheumatology, 2020, 72, 1772-1774.	5.6	3
240	Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry. Clinical Rheumatology, 2021, 40, 4039-4047.	2.2	3
241	Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 73-84.	0.8	3
242	Infectious agents breaking the immunological tolerance: The holy grail in rheumatoid arthritis reconsidered. Autoimmunity Reviews, 2022, 21, 103102.	5.8	3
243	Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. Annals of the Rheumatic Diseases, 2007, 66, 427-428.	0.9	2
244	Should We Consider Tumor Necrosis Factor as the Only Target in Spondyloarthritides?. Journal of rheumatology Supplement, The, 2012, 89, 94-96.	2.2	2
245	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmunity Reviews, 2018, 17, 1251-1258.	5.8	2
246	HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?. RMD Open, 2020, 6, e001171.	3.8	2
247	Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry―by Sparks <i>et al</i> . Annals of the Rheumatic Diseases, 2023, 82, e157-e157.	0.9	2
248	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clinical and Experimental Rheumatology, 2017, 35, 919-928.	0.8	2
249	Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 339-343.	3.3	1
250	B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids. Acta Diabetologica, 2008, 45, 195-196.	2.5	1
251	Infections, rheumatisms and autoimmunity. Future Rheumatology, 2008, 3, 223-225.	0.2	1
252	Biologics use in sle in 23 centers – data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.	0.9	1

#	Article	IF	CITATIONS
253	THU0532â€Distribution of Body Mass Index and Metabolic Syndrome in Patients with Inflammatory Autoimmune Diseases from a Single Italian Centre. Annals of the Rheumatic Diseases, 2013, 72, A344.1-A344.	0.9	1
254	AB0465â€Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity. Annals of the Rheumatic Diseases, 2013, 71, 664.5-664.	0.9	1
255	Response to letter by Aramugakaniet al. Annals of the Rheumatic Diseases, 2014, 73, e21-e21.	0.9	1
256	THU0525â€Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 364.3-365.	0.9	1
257	Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al. Arthritis and Rheumatology, 2016, 68, 553-553.	5.6	1
258	Comment on "Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study― Clinical Rheumatology, 2016, 35, 839-840.	2.2	1
259	FRI0388â€SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM. , 2019, , .		1
260	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. Rheumatology, 2020, 59, 1782-1783.	1.9	1
261	RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2025609118.	7.1	1
262	Cryoprecipitation.in vitro studies on fibronectin as an independent cryoprecipitagogue. Research in Clinic and Laboratory, 1986, 16, 315-20.	0.3	1
263	Indomethacin-Related Serum Sickness-Like Illness with IgM Lambda Cryoparaprotein?. Acta Haematologica, 1985, 73, 45-46.	1.4	0
264	Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 105-111.	0.3	0
265	Introduction. Autoimmunity Reviews, 2007, 7, 95.	5.8	Ο
266	Chapter 8 Gastrointestinal Involvement in Systemic Vasculitis. Handbook of Systemic Autoimmune Diseases, 2008, 8, 83-298.	0.1	0
267	Association of autoimmune diseases to allele 2 of the 3' immuno-globulines HS1.2 enhancer bearing an NF-&x03BAB binding site Nature Precedings, 2009, , .	0.1	Ο
268	B cell receptor repertoire analysis in clinically involved and uninvolved skin of systemic sclerosis patients treated with CD20 depletion therapy: baseline and follow-up. Annals of the Rheumatic Diseases, 2011, 70, A62-A63.	0.9	0
269	FRI0096â€Haq baseline values in an international registry of ra patients during the era of biologic terapies: the 2013 meteor database Annals of the Rheumatic Diseases, 2013, 72, A402.1-A402.	0.9	0
270	AB0770â€Rheuma-card: involvement of the patient through a secure systems access into the treat to target strategy in rheumatology Annals of the Rheumatic Diseases, 2013, 72, A1025.1-A1025.	0.9	0

#	Article	IF	CITATIONS
271	SAT0199â $\in$ An estimate of the proportion of patients with sle receiving off-label treatment with rituximab in european countries. Annals of the Rheumatic Diseases, 2013, 71, 539.1-539.	0.9	0
272	SAT0175â€Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study. Annals of the Rheumatic Diseases, 2013, 72, A640.2-A641.	0.9	0
273	OP0274â€Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins. Annals of the Rheumatic Diseases, 2015, 74, 175.3-176.	0.9	0
274	RHEUMATOID ARTHRITIS: PATHOGENESIS204. CHARACTERIZATION OF SYNOVIUM TISSUES MACROPHAGE OI RHEUMATOID ARTHRITIS PATIENTS. Rheumatology, 2017, 56, .	- 1.9	0
275	03.13â€Synovial tissue of ra patients in remission contains a unique population of regulatory macrophages. , 2017, , .		0
276	OP0208â€Synovial tissue of ra patients in remission contains a unique population of regulatory macrophages. , 2017, , .		0
277	THU0366â€Castrointestinal infections in patients with spondyloarthritis treated with anti-tnf drugs: results of gisea register. , 2017, , .		0
278	168 Body mass index does not influence the efficacy of abatacept in patients with psoriatic arthritis: results from the ASTRAEA trial. Rheumatology, 2018, 57, .	1.9	0
279	SAT0003â€Synovial tissue cd1c+ dendritic cells in rheumatoid arthritis express high levels of the epigenetic regulator of inflammation, microrna-155 and inflammatory cytokines. , 2018, , .		0
280	PS1:9â€B cell subpopulations in lupus nephritis patients: correlations with disease onset and outcomes. , 2018, , .		0
281	AB0253â€BIOMARKERS OF CLINICAL RESPONSE TO IL6-R BLOCKADE IN DMARDS INCOMPLETE RESPONDERS (AR-BIOM TRIAL): IL23 AND BAFF AS BIOLOGICAL TARGETS, AND ALBUMIN AS BIOLOGICAL PREDICTOR. , 2019, , .		0
282	SAT0073â€STAT3/STAT5 BALANCE AS A BIOMARKER IN RA: CTLA4-IG AND T CELL DIFFERENTIATION THROUGH STAT SIGNALING. , 2019, , .		0
283	AB0515â€OBESITY AND WEIGHT LOSS IMPACT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. , 2019, , .		0
284	AB0460â€USE OF PLATELET RICH PLASMA (PRP) IN TREATMENT OF DRY EYE SYNDROME IN THE PATIENTS WITH SJÖGREN SYNDROME: PRELIMINARY RESULTS. , 2019, , .	1	0
285	SATO201â€CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): THE ROLE OF TRADITIONA CARDIOVASCULAR RISK AND SLE-RELATED FACTORS. , 2019, , .	L	0
286	O14 Semi-quantitative assessment of synovial inflammation on US guided synovial membrane biopsy is contingent to disease phase, autoimmune profile and treatment response in RA: a large single center experience. Rheumatology, 2020, 59, .	1.9	0
287	P234 Characterisation of human synovial tissue dendritic cells in rheumatoid arthritis patients. Rheumatology, 2020, 59, .	1.9	0
288	P189â€Antiphospholipid antibodies and vascular renal lesions as prognostic factors in lupus nephritis. , 2020, , .		0

#	Article	IF	CITATIONS
289	Rheumatologic Symptoms in Patients with Mixed Cryoglobulinemia. , 2012, , 185-190.		0
290	THU0028â€Interleukin-6 receptor inhibition, as first-line b-dmard, affects b cell subpopulations distribution through epigenetic modifications in rheumatoid arthritispatients. , 2018, , .		0
291	THU0441â€Endothelial disfunction in polymyalgia rheumatica. , 2018, , .		0
292	AB0202â€Glucocorticoids in the initial treat-to-target strategy of early rheumatoid arthritis. , 2018, , .		0
293	SAT0223â€Predictive factors of early failure to first line treatment with methotrexate in patients with rheumatoid arthritis. results from the gisea registry , 2018, , .		Ο
294	SAT0193â€Early discontinuation of first line biological treatment with etanercept in patients with rheumatoid arthritis: results from the italian gisea registry. , 2018, , .		0
295	THU0234â€Bmi does not affect clinical outcome in psoriatic arthritis patients treated with tight control strategy. , 2018, , .		0
296	FRIOOO2â€Analysis of b cells and t cells subpopulations and collagen specific t cell repertoire in juvenile idiopathic arthritis patients. , 2018, , .		0
297	AB0759â€The assessment of gastrointestinal tract involvement through ucla sctc git 2.0 questionnaire identifies scleroderma patients with reduced bone mineral density. , 2018, , .		0
298	FRI0574â€RENAL TISSUE EPIGENETIC BIOMARKERS' CHARACTERIZATION IN PATIENTS WITH LUPUS NEPHR PARAMETERS OF DISEASE ACTIVITY, REMISSION AND FLARE. Annals of the Rheumatic Diseases, 2020, 79, 889.2-890.	ITIS AS 0.9	0
299	SAT0224â€ANTIPHOSPHOLIPID ANTIBODIES AND VASCULAR RENAL LESIONS AS PROGNOSTIC FACTORS IN LUPUS NEPHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1055.3-1055.	0.9	0
300	THU0287â€EVALUATION OF PREDICTIVE FACTORS OF WORSE PROGNOSIS IN LUPUS NEPHRITIS: FOCUS ON NEW PATHOGENETIC PATHWAYS. Annals of the Rheumatic Diseases, 2020, 79, 370.3-370.	0.9	0
301	AB0102â€SPECIALIZED PRO-RESOLVING MEDIATOR RECEPTORS AS INFLAMMATORY RESOLUTION BIOMARKEI IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1350.3-1350.	RS 0.9	0